Shares of BioXcel Therapeutics Inc. (BTAI) skyrocketed over 40% in premarket trading on Wednesday following the announcement that an independent audit of their Alzheimer's trial data revealed no issues affecting the integrity and reliability of the data.

The audit specifically focused on data obtained from a single site involved in BioXcel's late-stage trial for an experimental treatment targeting Alzheimer's-related agitation in individuals aged 65 and older. Based on the findings of the audit, BioXcel expressed confidence that the phase 3 trial data released in June could support a regulatory application for the approval of their treatment, BXCL501.

Concerns regarding the trial data initially emerged in late June when a regulatory filing by BioXcel stated that they had discovered a principal investigator associated with the trial who may have falsified emails purportedly demonstrating the timely submission of certain safety data. In response, the company promptly launched an investigation and engaged an independent third party to assess the data from the investigator's trial site.

Furthermore, on Wednesday, BioXcel disclosed that no additional instances of misconduct or fraud were found by the audit team.

In recent developments, BioXcel held a meeting with the U.S. Food and Drug Administration (FDA) to discuss their plans for the development of BXCL501. The company anticipates receiving the FDA meeting minutes in the first half of November.

Despite experiencing an 89% dip in share value year-to-date, BioXcel remains optimistic about the future, especially with the positive outcome of the independent audit. In comparison, the S&P 500 index has seen a 10.6% increase.

This news reaffirms BioXcel's commitment to advancing medical research for Alzheimer's and their dedication to ensuring the reliability of trial data. The discovery of no critical issues in the audit bolsters the company's chances of success when seeking regulatory approval for their promising treatment.

Atlas Copco Reports Strong Q3 Results, Expects Near-Term Weakness in Demand

Key Meeting of Anti-Israel Militant Groups

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Record Jump into U.S. Equities as Risks to Global Economy Heighten
News

Record Jump into U.S. Equities as Risks to Global Economy Heighten

Fund managers have made a significant shift from emerging markets to U.S. equities in response to growing risks in the g...

BioNTech Surpasses Expectations with Strong Q3 Earnings
News

BioNTech Surpasses Expectations with Strong Q3 Earnings

BioNTech surprises investors with strong Q3 earnings, outperforming projections and showing resilience in the face of ch...

Workers at Woodside Energy-Operated Offshore LNG Platforms Consider Strike Threat
News

Workers at Woodside Energy-Operated Offshore LNG Platforms Consider Strike Threat

Workers at Woodside Energy-operated offshore LNG platforms are deliberating a potential strike that may disrupt global g...

Nike Stock Rises on Strong Earnings
News

Nike Stock Rises on Strong Earnings

Nike's stock surges after impressive earnings report, boosting sportswear sector. Analysts express positive outlook, but...